Samsung BioLogics
ISIN KR7207940008
|WKN A2AUB1
Overview
Description
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical products. It operates through the CDMO and Biopharmaceutical Development and Commercialization business divisions. The CDMO division provides development services from cell line development to early clinical trials, including cell line development, processes, formulations, and analysis methods. The Biopharmaceutical Development and Commercialization division focuses on the development and commercialization of biosimilars and is conducting research and development on various disease fields such as autoimmune diseases, cancer diseases, ophthalmic diseases, and blood diseases. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Healthcare Healthcare Services Outsourced Development and Manufacturing Services South Korea
Financials
Key metrics
Market capitalisation, EUR | 44,455.84 m |
EPS, EUR | 10.32 |
P/B ratio | 6.55 |
P/E ratio | 65.96 |
Dividend yield | 0.00% |
Income statement (2024)
Revenue, EUR | 3,085.25 m |
Net income, EUR | 735.00 m |
Profit margin | 23.82% |
What ETF is Samsung BioLogics in?
There are 107 ETFs which contain Samsung BioLogics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Samsung BioLogics is the iShares Healthcare Innovation UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.